STAT+: GLP-1 drugs are almost single-handedly forcing employers to reconsider workers’ health care

The article, from STAT's Health Care Inc. newsletter, focuses on how GLP-1 medications are almost single-handedly driving employers to reconsider their approach to funding employee health care. The excerpt also mentions other health care business topics, including a hospital system's lawsuit against CVS Health and the potential changes from Medicaid cuts, but the central story is the financial strain GLP-1 drugs place on employer health plans.